Dr. Christopher P Cardozo, M.D.
Claim this profileJames J. Peters VA Medical Center
Studies Spinal Cord Injury
Studies Osteoporosis
4 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Christopher P Cardozo, M.D. is currently running
Neostigmine + Glycopyrrolate
for Neurogenic Bowel
Persons with spinal cord injury (SCI) have neurogenic bowel disorders which is associated with significant morbidity. The negative impact of bowel complications is often at the top of the list of problems reported by persons with SCI. Despite the magnitude of the problem of bowel dysfunction in persons with SCI, and the associated reduction in quality of life, this condition has yet to be effectively treated. The investigators have developed a novel dual drug combination to elicit a safe and predictable bowel evacuation (BE). The ability to move the bowel contents along to the rectum was severely impaired primary because of poor gut contractions on the left side of the colon, as shown by our team of investigators. To address this problem, a dual medication combination (neostigmine and glycopyrrolate) was developed that safely and predictably caused the bowel to empty after delivering these drugs into a vein (intravenously) or into the muscle bed (intramuscularly). Because no one likes needles, and because of the practical limits of administering medications on a routine basis by the use of needles, especially in persons with SCI because of their other health considerations, the investigators have devised a new approach: driving these medications across the skin and into the circulation of the body by applying an electrical current that is too small to feel (iontophoresis). The proposed research project to determine the safety of positively charged compounds (e.g., vitamin B12, NEO, and GLY) administered transcutaneously by the prototype wireless ION device and to compare the pharmacokinetic profiles of transcutaneous administration of NEO and GLY by the wireless ION device to a commercially available wired ION device. The potential administration of any number of other positively charged agents by this wireless prototype may be a clinically relevant outcome of this work. The ability to use a wireless ION device is far more practical for patients to use, especially those with SCI, which will permit the self-administration of these agents in the home setting to induce a bowel evacuation.
Recruiting1 award Phase < 1
Romosozumab + Denosumab
for Spinal Cord Injury
The objective of the proposed work is to determine whether administration for 12 months of romosozumab (evenity) followed by 12 months of denosumab (prolia) will maintain bone mass at the knee in subjects with chronic SCI.
Recruiting3 awards Phase 45 criteria
More about Christopher P Cardozo, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Christopher P Cardozo, M.D. has experience with
- Denosumab
- Romosozumab
- Romoszumab
- Placebo
- Transdermal Administration By A Novel Wireless Iontophoresis Device
Breakdown of trials Christopher P Cardozo, M.D. has run
Spinal Cord Injury
Osteoporosis
Sublesional Bone Loss
Paraplegia
Constipation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Christopher P Cardozo, M.D. specialize in?
Is Christopher P Cardozo, M.D. currently recruiting for clinical trials?
Are there any treatments that Christopher P Cardozo, M.D. has studied deeply?
What is the best way to schedule an appointment with Christopher P Cardozo, M.D.?
What is the office address of Christopher P Cardozo, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.